The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Development and validation of a novel prognostic model for disease-specific survival in patients with non-metastatic small cell carcinoma of the bladder.
 
Leonidas Nikolaos Diamantopoulos
No Relationships to Disclose
 
Daniel S Childs
Employment - Mayo Clinic
Honoraria - International Centers for Precision Oncology Foundation; IntrinsiQ; MJH Life Sciences; Targeted Oncology
Consulting or Advisory Role - Janssen Biotech (Inst); Novartis (Inst)
Research Funding - Janssen Biotech (Inst)
Travel, Accommodations, Expenses - Prostate Cancer Foundation
 
Akeem Ronell Lewis
No Relationships to Disclose
 
Fabrice Lucien
No Relationships to Disclose
 
Spyridon P. Basourakos
No Relationships to Disclose
 
Adam McLain Kase
No Relationships to Disclose
 
Parminder Singh
Honoraria - Curio Science; Medpage/ASCO
Consulting or Advisory Role - AVEO; Bayer; EMD Serono; ImmunityBio; Janssen Oncology; Seattle Genetics/Astellas (Inst)
Research Funding - EMD Serono (Inst)
(OPTIONAL) Uncompensated Relationships - Seagen
 
Mark Tyson
No Relationships to Disclose
 
Stephen A. Boorjian
Consulting or Advisory Role - ArTara Therapeutics; FerGene; Ferring; Prokarium
 
Lance C. Pagliaro
Research Funding - Exelixis (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
 
Brian Addis Costello
Speakers' Bureau - Clinical Care Options/NCCN (Inst)
Research Funding - GlaxoSmithKline/Novartis (Inst)
 
Jacob Orme
Consulting or Advisory Role - NaNotics
Patents, Royalties, Other Intellectual Property - Patents regarding PD-L1 cleavage and immunotherapy resistance in multiple cancers. (Inst)